Phentermine and Topiramate
Qsymia is a prescription weight loss medication combining two active ingredients, phentermine and topiramate, designed to help adults manage obesity or achieve weight loss when other methods alone have been insufficient. It works as an adjunct to a reduced-calorie diet and increased physical activity for long-term weight management.
Qsymia is a prescription weight loss aid combining phentermine and topiramate for chronic weight management in adults with obesity or weight-related health conditions.
Key facts at a glance
- RxNorm
- 1372703
- Generic
- Qsymia
- Class
- brand-name
- Brands
- —
- Availability
- rx
- Lactation
- unknown
- Routes
- —
- Forms
- —
- Regions
- US, EU, CN, JP
- Monitoring
- —
This page is for informational purposes only.
Do not use this information to diagnose yourself or to replace a physician's advice. Always consult a qualified healthcare provider before starting, stopping, or changing any medication. If you believe you are experiencing a medical emergency, call your local emergency number immediately.
Qsymia is indicated for weight loss and weight maintenance in adults with obesity (BMI ≥30 kg/m²) or overweight adults (BMI ≥27 kg/m²) with at least one weight-related comorbidity such as hypertension, type 2 diabetes, or dyslipidemia. It should be used alongside a reduced-calorie diet and exercise program.
Qsymia combines two mechanisms: phentermine acts as an appetite suppressant by stimulating the central nervous system to reduce hunger signals, while topiramate appears to promote satiety and reduce appetite through its effects on neurotransmitter activity. Together, these components help patients consume fewer calories.
Qsymia is contraindicated during pregnancy due to risk of birth defects. Common side effects include tingling sensations, dizziness, altered taste, insomnia, and constipation. It should not be used in patients with glaucoma, hyperthyroidism, or recent MAOI use. Patients should have regular monitoring for heart rate changes and should not discontinue abruptly. This medication requires enrollment in a restricted distribution program due to its teratogenic potential.
Official drug label
WellAlly may earn a referral fee from linked resources at no extra cost to you. Editorial content is never influenced by commercial relationships.
This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 9, 2026. · Read our editorial policy